Adalimumab, azathioprine or mesalazine for the prevention of postoperative recurrence of Crohn's disease
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2014
Price : $35 *
At a glance
- Drugs Adalimumab (Primary) ; Azathioprine; Mesalazine
- Indications Crohn's disease
- Focus Therapeutic Use
- 26 Jun 2013 New trial record
- 18 May 2013 Primary endpoint 'Disease-recurrence-rate' has been met.
- 18 May 2013 Results presented at the Digestive Disease Week 2013.